What the FDA labels say about taking them together
Cabazitaxel and ritonavir
Cabazitaxel's FDA label of October 7, 2025 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name cabazitaxel. The cabazitaxel label: “Strong CYP3A inhibitors may increase plasma concentrations of cabazitaxel.”
Check it at the source: the cabazitaxel FDA label on DailyMed (effective October 7, 2025, Sanofi-Aventis U.S. LLC); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the cabazitaxel label say about ritonavir?
Cabazitaxel label, drug interactionsStrong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase plasma concentrations of cabazitaxel.
Source: FDA drug label (Jevtana), Sanofi-Aventis U.S. LLC, effective October 7, 2025 (SPL set de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa), via openFDA; the full label on DailyMed
What does the ritonavir label say about cabazitaxel?
Ritonavir's label (effective July 23, 2026) does not name cabazitaxel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cabazitaxel | Ritonavir | |
|---|---|---|
| Labeled for | Prostate cancer | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once